Goldman Sachs Group Inc Kezar Life Sciences, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 297,774 shares of KZR stock, worth $1.94 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
297,774
Previous 1,019,176
70.78%
Holding current value
$1.94 Million
Previous $611,000
62.52%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding KZR
# of Institutions
61Shares Held
38.4MCall Options Held
13.8KPut Options Held
600-
Suvretta Capital Management, LLC New York, NY7.17MShares$46.7 Million0.22% of portfolio
-
Avidity Partners Management LP Dallas, TX5.03MShares$32.8 Million0.24% of portfolio
-
Tang Capital Management LLC San Diego, CA3.64MShares$23.7 Million0.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.74MShares$17.9 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY2.51MShares$16.4 Million0.33% of portfolio
About Kezar Life Sciences, Inc.
- Ticker KZR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,369,504
- Market Cap $446M
- Description
- Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...